Cantillo, E., Zemla, T., Moroney, J., Alvarez, E., Lin, Y., DiLallo, G., … Slomovitz, B. (2024). AFT-50 EndoMAP: A phase Ib/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer. In Gynecologic Oncology (Vol. 190, pp. S290–S291). Elsevier BV. https://doi.org/10.1016/j.ygyno.2024.07.432

Cantillo, Evelyn, Tyler Zemla, John Moroney, Edwin Alvarez, Yvonne Lin, Gillian DiLallo, Joyce Liu, et al. “AFT-50 EndoMAP: A phase Ib/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.” In Gynecologic Oncology, 190:S290–91. Elsevier BV, 2024. https://doi.org/10.1016/j.ygyno.2024.07.432.

Cantillo E, Zemla T, Moroney J, Alvarez E, Lin Y, DiLallo G, et al. AFT-50 EndoMAP: A phase Ib/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer. In: Gynecologic Oncology. Elsevier BV; 2024. p. S290–1.

Cantillo, Evelyn, et al. “AFT-50 EndoMAP: A phase Ib/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.” Gynecologic Oncology, vol. 190, Elsevier BV, 2024, pp. S290–91. Crossref, doi:10.1016/j.ygyno.2024.07.432.

Cantillo E, Zemla T, Moroney J, Alvarez E, Lin Y, DiLallo G, Liu J, Secord AA, Nixon A, Mandrekar S, Matulonis U, Kozono D, Slomovitz B. AFT-50 EndoMAP: A phase Ib/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer. Gynecologic Oncology. Elsevier BV; 2024. p. S290–S291.